Batoprotafib (TNO155)

Catalog No.S8987 Batch:S898701

Print

Technical Data

Formula

C18H24ClN7OS
Molecular Weight 421.95 CAS No. 1801765-04-7
Solubility (25°C)* In vitro DMSO 84 mg/mL (199.07 mM)
Ethanol 5 mg/mL (11.84 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 4.200mg/ml (9.95mM) Taking the 1 mL working solution as an example, add 50 μL 84 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Batoprotafib (TNO155) is an inhibitor of protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2 /src homology region 2 domain phosphatase /PTPN11) with IC50 of 0.011 µM, and has potential antineoplastic activity.
Targets
SHP-2 [1]
(Cell-free assay)
0.011 μM
In vitro

Batoprotafib (TNO155) inhibits KYSE520 pERK and KYSE520 5-day cell proliferation with IC50 of 0.008 µM and of 0.100 µM, respectively. Its off-target IC50 are 18 µM, 6.9 µM, 11 µM and > 30μM for Cav1.2, VMAT, SST3 and all others, respectively.
In vivo

Batoprotafib (TNO155) is a potent and selective first-in-class inhibitor of wild-type SHP2, with high oral bioavailability and BCS class I properties. Its oral bioavailability in mouse, rat and monkey are 78%, 86%, and 60%, respectively.
Density g/mL

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    PC-14 cells

  • Concentrations

    3 μM

  • Incubation Time

    24 h

  • Method

    PC-14 cells were treated with nazartinib (0.1 or 0.3 µM), 3 µM Batoprotafib (TNO155), or the combination of nazartinib and it for 4 hours or 24 hours.

References

  • https://colectivogist.files.wordpress.com/2017/11/nuevos-ensayos-geis-2017.pdf
  • https://pubmed.ncbi.nlm.nih.gov/33046519/

Selleck's Batoprotafib (TNO155) Has Been Cited by 16 Publications

PD1-induced Shp2 condensation organizes inhibitory signalosomes through selective substrate partitioning [ bioRxiv, March 11 2026, nan] PubMed: 41959162
EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma [ Molecular Cancer Therapeutics, December 01 2023, 1479-1492] PubMed: 37710057
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From the In Vitro Experiments [ Journal of Thoracic Oncology, August 2021, 1321-1332]
Mapping the landscape of genetic dependencies in chordoma [ Nature Communications, April 06 2023, 1933] PubMed: 37024492
Impaired MC3T3-E1 osteoblast differentiation triggered by oncogenic HRAS is rescued by the farnesyltransferase inhibitor Tipifarnib [ Sci Rep, 2025, 15(1):6832] PubMed: 40000861
A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance [ Res Sq, 2025, rs.3.rs-7032881] PubMed: 40799749
A Hotspot Phosphorylation Site on SHP2 Drives Oncoprotein Activation and Drug Resistance [ bioRxiv, 2025, 2025.06.11.659120] PubMed: 40667115
Preclinical translational platform of neuroinflammatory disease biology relevant to neurodegenerative disease [ J Neuroinflammation, 2024, 21(1):37] PubMed: 38297405
Allosteric inhibitor of SHP2 enhances macrophage endocytosis and bacteria elimination by increasing caveolae activation and protects against bacterial sepsis [ Pharmacol Res, 2024, 201:107096] PubMed: 38320736
KRASG 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening [ Mol Oncol, 2024, 10.1002/1878-0261.13725] PubMed: 39253995

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.